Safety of antidepressants in the elderly

Bibliography

• VESTAL RE: Aging and pharmacology. Cancer (1997) 80:1302–1310.
   PubMed Web of Science ®Google Scholar
• SEMLA TP: Essentials of geriatric pharmacotherapy. Resid. Staff Physician (2002) 48(2):25–31.
   Google Scholar
• VON MOLTKE LL, GREENBLATT DJ: Drug transporters revisited. J. Clin. Psychopharmacol. (2001) 21:1–3.
   PubMed Web of Science ®Google Scholar
• GREENBLATT DJ, PATKI KC, VON MOLTKE LL, SHADER RI: Drug interactions with grapefruit juice: an update./ Clin. Psychopharmacol. (2001) 21(0357–359.
   PubMed Web of Science ®Google Scholar
• KETTER TA, FLOCKHART DA, POST RM et al.: The emerging role of cytochrome P450 3A in psychopharmacology. J. Clin. Psychopharmacol. (1995) 15:387–398.
   PubMed Web of Science ®Google Scholar
• POLLOCK BG: Adverse reactions of antidepressants in elderly patients. J. Clin. Psychiatry (1999) 60\(Suppl. 20):4–8.
   Google Scholar
• COTE LJ, KREMZNER LT: Biochemical changes in normal aging in human brain. In: The Dementias. Mayeux R, Rosen W (Eds), Raven Press, New York (1983):19–30.
   Google Scholar
• BEERS MH: Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch. Intern. Med. (1997) 157:1531–1536.
   PubMed Web of Science ®Google Scholar
• DAVIDSON J: Pharmacological treatment. In: Textbook of Geriatric Psychiatry (2nd edn). Busse EW, Blazer DG (Eds), American Psychiatric Association Press, Washington DC (1996):364.
   Google Scholar
• KATZ IR, SIMPSON GM, JETHANANDANI V, COOPER T, MUHLY C: Steady state pharmacokinetics of nortriptyline in the frail elderly. Neuropsychopharmacology (1989) 2(3):229–236.
   PubMed Web of Science ®Google Scholar
• KUMAR V, SMITH RC, REED K, LEELAVATHI DE: Plasma levels and effects of nortriptyline in geriatric depressed patients. Acta Psychiatr. Scand. (1987) 75(0:20–28.
   PubMedGoogle Scholar
• NELSON JC, MAZURE CM, JATLOW PI: Desipramine treatment of major depression in patients over 75 years of age. J. Clin. Psychopharmacol. (1995) 15(2):99–105.
   PubMed Web of Science ®Google Scholar
• NIES A, ROBINSON DS, FRIEDMAN MJ et al.: Relationship between age and tricyclic antidepressant plasma levels. Am. J. Psychiatry (1977) 134(7):790–793.
   PubMed Web of Science ®Google Scholar
• SOLAI LK, MULSANT BH, POLLOCK BG et al.: Effect of sertraline on plasma nortriptyline levels in depressed elderly. J. Clin. Psychiatry (1997) 58(10):440–443.
   PubMed Web of Science ®Google Scholar
• HOLROYD KA, O'DONNELL FJ, STENSLAND M, LIPCHIK GL, CORDINGLEY GE, CARLSON BW: Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy, and their combination: a randomized controlled trial. /AMA (2001) 285(17):2208–2215.
   PubMed Web of Science ®Google Scholar
• PANERAI AE, MONZA G, MOVILIA P, BIANCHI M, FRANCUCCI BM, TIENGO M: A randomized, within-patient, cross-over, placebo-controlled trial on the efficacy and tolerability of the tricyclic antidepressants chlorimipramine and nortriptyline in central pain. Acta NeuroL Scand. (1990) 82(1):34–38.
   PubMed Web of Science ®Google Scholar
• WATSON CP, EVANS RJ, REED K, MERSKEY H, GOLDSMITH L, WARSH J: Amitriptyline versus placebo in postherpetic neuralgia. Neurology (1982) 32(6):671–673.
   PubMed Web of Science ®Google Scholar
• ATKINSON JH, SLATER MA, WILLIAMS RA et al.: A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain. Pain (1998) 76(3):287–296.
   PubMed Web of Science ®Google Scholar
• MULSANT BH, POLLOCK BG, NEBES R et al.: A twelve-week, double-blind, randomized comparison of nortriptyline and paroxetine in older depressed inpatients and outpatients. Am. J. Geriatr. Psychiatry (2001) 9(0406–414.
   PubMed Web of Science ®Google Scholar
• POLLOCK BG, MULSANT BH, NEBES R et al.: Serum anticholinergicity in elderly depressed patients treated with paroxetine or nortriptyline. Am. J. Psychiatry (1998) 155(8):1110–1112.
   PubMed Web of Science ®Google Scholar
• KNEGTERING H, EIJCK M, HUIJSMAN A: Effects of antidepressants on cognitive functioning of elderly patients. A review. Drugs Aging (1994) S(3):192–199.
   Google Scholar
• YOUNG RC, MATTIS S, ALEXOPOULOS GS, MEYERS BS, SHINDLEDECKER RD, DHAR AK Verbal memory and plasma drug concentrations in elderly depressives treated with nortriptyline. Psychopharmacol Bull. (1991) 27(3):291–294.
   PubMed Web of Science ®Google Scholar
• MAI\40 DC, SWEET RA, MULSANT BH et al.: Effect of nortriptyline and paroxetine on extrapyramidal signs and symptoms: a prospective double-blind study in depressed elderly patients. Am. J. Geriatr. Psychiatry (2000) 8(3):226–231.
   Google Scholar
• MILLER MD, CURTISS El, MARINO L et al.: Long-term ECG changes in depressed elderly patients treated with nortriptyline. A double-blind, randomized, placebo-controlled evaluation. Am. J. Geriatr. Psychiatry (1998) 6(1):59–66.
   PubMed Web of Science ®Google Scholar
• MCCUE R, GEROGOTAS A, NAGACHANDRAN Net al.: Plasma levels of nortriptyline and 10-hydroxynortriptyline and treatment-related electrocardiographic changes in the elderly depressed. J. Psychiatr. Res. (1989) 23(1):73–79.
   Google Scholar
• DRAGANICH LF, ZACNY J, KLAFTA J, KARRISON T: The effects of antidepressants on obstructed and unobstructed gait in healthy elderly people. J. Gerontol. A. Biol. Sci. Med. Sci. (2001) 56(1):M36–M41.
   PubMed Web of Science ®Google Scholar
• BERNSTEIN J: Handbook of Drug Therapy in Psychiatry (3rd edn). Mosby-Year Book, Inc., St Louis, Missouri (1995):153–180.
   Google Scholar
• GARERI P, STILO G, BEVACQUA I, MATTACE R, FERRERI G, DE SARRO G: Antidepressant drugs in the elderly. Gen. Pharmacol. (1998) 30(4):465–475.
   PubMedGoogle Scholar
• GARERI P, FALCONI U, DE FAZIO P, DE SARRO G: Conventional and new antidepressant drugs in the elderly. Prog. Neurobiol. (2000) 61:353–396.
   PubMed Web of Science ®Google Scholar
• BALON R, MUFTI R, ARFKEN CL: A survey of prescribing practices for monoamine oxidase inhibitors. Psychiatr. Serv. (1999) 50(7):945–947.
   PubMed Web of Science ®Google Scholar
• SMALL GW: Treatment of geriatric depression. Depress. Anxiety (1998) 8\(Suppl. 1):32–42.
   Google Scholar
• ROSENZWEIG P, PATAT A, ZIELENIUK I, CIMAROSTI I, ALLAIN H, GANDON JM: Cognitive performance in elderly subjects after a single dose of befloxatone, a new reversible selective monoamine oxidase A inhibitor. Clin. Pharmacol. Ther. (1998) 64(2):211–222.
   PubMed Web of Science ®Google Scholar
• ROOSE SP, GLASSMAN AH, ATTIA E, WOODRING S: Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am. J. Psychiatry (1994) 151(12):1735–1739.
   PubMed Web of Science ®Google Scholar
• LIU BA, MITTMANN N, KNOWLES N, SANDRA R, SHEAR NH: Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. CMAJ (1996) 155(5):519–527.
   PubMed Web of Science ®Google Scholar
• ENSRUD KE, BLACKWELL TL, MANGIONE CM et al.: Central nervous system-active medications and risk for falls in older women. J. Am. Geriatr. Soc. (2002) 50(10):1629–1637.
   PubMed Web of Science ®Google Scholar
• AGOSTINI JV, TINITTI ME: Drugs and falls: rethinking the approach to medication risk in older adults. J. Am. Geriatr. Soc. (2002) 50(10):1744–1745.
   PubMed Web of Science ®Google Scholar
• •Addresses the important issue of centrally active medications and the risk of falling in older adults. With the risk of older individuals falling already high, knowledge of contributing risk factors is essential, and this is an excellent review of this subject.
   Google Scholar
• LEIPZIG RM, CUMMING RG, TINETTI ME: Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J. Am. Geriatr. Soc. (1999) 47(1):30–39.
   PubMed Web of Science ®Google Scholar
• THAPA PB, GIDEON, P, COST TW et al.: Antidepressants and the risk of falls among nursing home residents. N Engl. J. Med. (1998) 339:875–882.
   PubMed Web of Science ®Google Scholar
• JOO JH, LENZE EJ, MULSANT BH et al.:Risk factors for falls during treatment of late-life depression. J. Clin. Psychiatry (2002) 63(10936–941.
   Google Scholar
• SCHATZBERG AF, COLE JO, DE BATTISTA C: Pharmacological treatment. In: Manual of Clinical Psychopharmacology (3rd edn). American Psychiatric Association Press, Washington DC (1997):72,82.
   Google Scholar
• KAPUR S, REMINGTON G: Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psychiatry (1996) 153(4):466–476.
   PubMed Web of Science ®Google Scholar
• •An important review of the interactions between serotonergic and dopaminergic neurons. Whilst the review is written in the context of schizophrenia, it is a good way of understanding the mechanism of potential side effects of the many medications we prescribe, and the mechanism of Parkinsonism from SSRI administration is also elucidated.
   Google Scholar
• DELEAGNELLO G, CERAVOLO R, NUTT A et al.: SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. Clin. Neuropharmacol. (2001) 24(4):221–227.
   PubMed Web of Science ®Google Scholar
• ALEXOPOULOS GS, KATZ IR, REYNOLDS CF, CARPENTER D, DOCHERTY JP: Pharmacotherapy of depressive disorders in older patients. In: The Expert Consensus Guideline Series: Postgraduate Medicine Special Report. McGraw Hill, New York (2001):1–86.
   Google Scholar
• LANE R, BALDWIN D: Selective serotonin reuptake inhibitor-induced serotonin syndrome: review J. Clin. Psychopharmacol. (1997) 17(3):208–221.
   PubMed Web of Science ®Google Scholar
• ••Reviews the signs and symptoms ofserotonin syndrome and the medications that when administered in combination may cause this life-threatening condition.
   Google Scholar
• BYMASTER FP, ZHANG W, CARTER PA et al.: Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (2002) 60(4):353–361.
   Google Scholar
• STRIK JJ, HONIG A, LOUSBERG R et al.: Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, Expert Op/n. Drug Saf. (2003) 2(4) placebo-controlled trial. Psychosom. Med. (2000) 62(6):783–789.
   Google Scholar
• ROOSE SP, GLASSMAN AH, ATTIA E, WOODRING S, GIARDINA EG, BIGGER JT Jr: Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am. J. Psychiatry (1998) 155(5):660–665.
   PubMed Web of Science ®Google Scholar
• WIART L, PETIT H, JOSEPH PA, MAZAUX JM, BARAT M: Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke (2000) 31(8):1829–1832.
   PubMed Web of Science ®Google Scholar
• CONNOLLY VM, GALLAGHER A, KESSON CM: A study of fluoxetine in obese elderly patients with type 2 diabetes. Diabet. Med. (1995) 12(5):416–418.
   PubMed Web of Science ®Google Scholar
• FINKEL SI, RICHTER EM, CLARY CM, BATZAR E: Comparative efficacy of sertraline vs. fluoxetine in patients age 70 or over with major depression. Am. J. Geriatr. Psychiatry (1999) 7(3):221–227.
   Google Scholar
• RONFELD RA, TREMAINE LM, WILNER KD: Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin. Pharmacokinet. (1997) 32\(Suppl. 1):22–30.
   Google Scholar
• RODRIGUEZ DE LA TORRE B, DREHER J, MALEVANY I et al.: Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther. Drug. Monit. (2001) 23(4):435–440.
   PubMed Web of Science ®Google Scholar
• ROOSE SP, LAGHRISSI-THODE F, KENNEDY JS et al.: Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA (1998) 279(4):287–291.
   PubMed Web of Science ®Google Scholar
• NELSON JC, KENNEDY JS, POLLOCK BG et al.: Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. Am. J. Psychiatry (1999) 156(7):1024–1028.
   PubMed Web of Science ®Google Scholar
• POLLOCK BG, MULSANT BH, NEBES R et al.: Serum anticholinergicity in elderly depressed patients treated with paroxetine or nortriptyline. Am. J. Psychiatry (1998) 155(8):1110–1112.
   PubMed Web of Science ®Google Scholar
• FURLAN PM, KALLAN MJ, TEN HAVE T, POLLOCK BG, KATZ I, LUCKI I: Cognitive and psychomotor effects of paroxetine and sertraline on healthy elderly volunteers. Am. J. Geriatr. Psychiatry (2001) 9(4):429–438.
   PubMed Web of Science ®Google Scholar
• MAI\40 DC, POLLOCK BG, MULSANT B et al.: Effects of nortriptyline and paroxetine on postural sway in depressed elderly patients. Am. J. Geriatr. Psychiatry (2002) 10(2):199–205.
   Google Scholar
• LAGHRISSI-THODE F, POLLOCK BG, MILLER MC, MULSANT BH, ALTIERI L, FINKEL MS: Double-blind comparison of paroxetine and nortriptyline on the postural stability of late-life depressed patients. PsychopharmacoL Bull. (1995) 31(4):659–663.
   PubMed Web of Science ®Google Scholar
• DRAGANICH LF, ZACNY J, KLAFTA J, KARRISON T: The effects of antidepressants on obstructed and unobstructed gait in healthy elderly people. J. GerontoL A. Biol. Sci. Med. Sci. (2001) 56(1):M36–M41.
   PubMed Web of Science ®Google Scholar
• DUNBAR GC: Paroxetine in the elderly: a comparative meta-analysis against standard antidepressant pharmacotherapy. Pharmacology (1995) 51(3):137–144.
   PubMed Web of Science ®Google Scholar
• WILLETTS J, LIPPA A, BEER B: Clinical development of citalopram. J. Clin. PsychopharmacoL (1999) 19(5 Suppl. 1):536–546.
   Google Scholar
• LIPPA AS, BEER B, CANCR R: Introduction: overview of citalopram. J. Clin. Psychopharmacol. (1999) 19(5 Suppl. 1):S1–53.
   Google Scholar
• POPIK P: Preclinical pharmacology of citalopram. J. Clin. PsychopharmacoL (1999) 19(5 Suppl. 1):54–522.
   Google Scholar
• PERSONNE M, PERSSON H, SJOBERG G: Citalopram toxicity. Lancet (1997) 350:518–519.
   PubMed Web of Science ®Google Scholar
• KLYSNER R, BENT-HANSEN J, HANSEN HL, LUNDE M, PLEIDRUP E, POULSEN D et al.: Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy. Br. J. Psychiatry (2002) 181:29–35.
   PubMed Web of Science ®Google Scholar
• KYLE CJ, PETERSEN HEH, OVERO KF: Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice. Depress. Anxiety (1998) 8:147–153.
   PubMedGoogle Scholar
• THOMAS KV, HOLIMON TD: Citalopram versus other selective serotonin-reuptake inhibitors. Am. J. Health Sys. Pharm. (1999) 56(21):2242–2244.
   PubMed Web of Science ®Google Scholar
• GREENBLATT DJ, VON MOLTKE LL, JEROLD S, SHADER RI: Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions. J. Clin. PsychopharmacoL (1999) 19(5 Suppl. 1):523–535.
   Google Scholar
• GLEASON OC, YATES WR, ISBELL MD, PHILIPSEN MA: An open trial of citalopram for major depression in patients with hepatitis C. J. Clin. Psychiatry (2002) 63(3):194–198.
   PubMed Web of Science ®Google Scholar
• BURKE WJ, ROTHSCHILD T, DE SWART H: Safety experience with escitalopram in the treatment of elderly patients with depression. Annual Scientific Meeting of the American Association for Geriatric Psychiatry, Honolulu, HI, May 2003.
   Google Scholar
• GURLAND BJ, KATZ S, CHEN J: Index of affective suffering. Linking a classification of depressed mood to impairment in quality of life. Am. J. Geriatr. Psychiatry. (1997) 5:192–210.
   PubMed Web of Science ®Google Scholar
• KARLSSON I, GODDERIS J, AUGUSTO DE MENDONCA LIMA C et al.: A randomized, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia. Int. J. Geriatr. Psychiatry (2000) 15:295–305.
   Google Scholar
• POLLOCK BG, MULSANT BH, ROSEN J et al.: Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am. J. Psychiatry (2002) 159:460–465.
   PubMed Web of Science ®Google Scholar
• GREENBLATT DJ, VON MOLTKE LL, HARMATZ JS, SHADER RS: Drug interactions with newer antidepressants: role of human cytochromes P450.1. Clin. Psychiatry (1998) 59\(Suppl. 15):19–27.
   Google Scholar
• BUCHBERGER R, WAGNER W: Fluvoxamine: safety profile in extensive post-marketing surveillance. Pharmacopsychiatry (2002) 35(3):101–108.
   PubMed Web of Science ®Google Scholar
• STAHL SM: Newer depressants and mood stabilizers. In: Essential Psychopharmacology: Neuroscientific Basis and Practical Applications (2nd edn). Cambridge University Press, New York (2000):245–295.
   Google Scholar
• SPINA E, SCORDO MG: Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging (2002) 19(4):299–320.
   PubMed Web of Science ®Google Scholar
• DEVANE DL, POLLACK BG: Pharmacokinetic considerations of antidepressant use in the elderly. J. Clin. Psychiatry (1999) 60(Suppl.):38–44.
   Google Scholar
• BARBHAIYA RH, BUCH, GREENE DS: A study of the effect of age and gender on 382 Expert Op/n. Drug Saf. (2003) 2(4) the pharmacokinetics of nefazodone after single and multiple doses. J. Clin. Pharmacol. (1996) 16:19–25.
   Google Scholar
• ABERNETHY DR, BARBEY JT, FRANC J et al.: Loratadine and terfenadine interaction with nefazodone: both antihistamines are associated with QTc prolongation. Clin. Pharmacol Ther. (2001) 69(3):96–103.
   PubMed Web of Science ®Google Scholar
• SCHWETZ BA: Warning on serzone. JAMA (2002) 287(9):1103.
   PubMed Web of Science ®Google Scholar
• SOMMER BR Personal communication with Bristol-Myers Squibb, Drug Information, Medical Communications Division, Stanford, CA, USA (August 6 2002).
   Google Scholar
• SAIZ-RUIZ J, IBANEZ A, DIAZ-MARSA M et al.: Nefazodone in the treatment of elderly patients with depressive disorders: a prospective, observational study. CNS Drugs (2002) 16(9):635–643.
   PubMed Web of Science ®Google Scholar
• PETROVIC M, PEVERNAGIE D, VAN DEN NOORTGATE N, MARIMAN A, MICHIELSEN W, AFSCHRIFT M: A programme for short-term withdrawal from benzodiazepines in geriatric hospital inpatients: success rate and effect on subjective sleep quality. Int. J. Geriatr. Psychiatry (1999) 14:754–760.
   PubMed Web of Science ®Google Scholar
• SALETU-ZYHLARZ GM, ABU-BAKR MH, ANDERER P et al.: Insomnia related to dysthymia: polysomnographic and psychometric comparison with normal controls and acute therapeutic trials with trazodone. Neuropsychobiology (2001) 44(3):139–149.
   PubMed Web of Science ®Google Scholar
• COSTABILE RA, SPEVAK M: Oral trazodone is not effective therapy for erectile dysfunction: a double-blind, placebo-controlled trial. J. Urol. (1999) 161:1819–1822.
   PubMed Web of Science ®Google Scholar
• AMORE M, RICCI M, ZANARDE R, PEREZ J, FERRARI G: Long-term treatment of geropsychiatric depressed patients with venlafaxine. J. Affect. Disord. (1997) 46:293–296.
   PubMed Web of Science ®Google Scholar
• TASMUTH T, HARTEL B, KALSO E: Venlafaxine in neuropathic pain following treatment of breast cancer. Eur. J. Pain. (2002) 6(1):17–24.
   PubMed Web of Science ®Google Scholar
• STAAB JP, EVANS DL: Efficacy of venlafaxine in geriatric depression. Depress. Anxiety (2000) 12(Suppl.):63–68.
   Google Scholar
• KIRBY D, HARRIGAN S, AMES D: Hyponatraemia in elderly psychiatric patients treated with selective serotonin reuptake inhibitors and venlafaxine: a retrospective controlled study in an inpatient unit. Int. J. Geriatr. Psychiatry (2002) 17:231–237.
   PubMed Web of Science ®Google Scholar
• CROFT H, SETTLE JR E, HOUSER T, BATEY SR, DONAHUE RM, ASCHER JA: A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin. Ther. (1999) 21(4):643–658.
   PubMed Web of Science ®Google Scholar
• NIEUWSTRATEN CE, DOLOVICH LR: Bupropion versus selective serotonin reuptake inhibitors for treatment of depression. Ann. Pharmacother. (2001) 35:1608–1613.
   PubMed Web of Science ®Google Scholar
• HESSE LM, VENKATAKRISHNAN K, COURT MH et al.: CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab. Dispos. (2000) 28(101176–1183.
   Google Scholar
• FENN H, KETTER TA: Personal communication, Stanford, CA, USA (2002).
   Google Scholar
• WEIHS KL, SETTLE EC, BATEY SR, HOUSER TL, DONAHUE RMJ, ASCHER JA: Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J. Clin. Psychiatry (2000) 61(3):196–202.
   PubMed Web of Science ®Google Scholar
• JEFFERSON JW: Cardiovascular effects of bupropion. J. Clin. Psychiatry (1993) 11 (monograph) :43–48.
   Google Scholar
• SCHATZBERG AF, KREMER C, RODRIGUEZ H, MURPHY GM Jr: Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am. J. Geriatr. Psychiatry (2002) 10(5)541–550.
   Google Scholar
• SHIMADA T, YAMAZAKI H, MIMURA M, INUI Y, GUENGERICH FP: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol Exp. Ther. (1994) 270:414–423.
   PubMed Web of Science ®Google Scholar